EndoGastric Solutions: Re-Inventing GERD Therapy
Executive Summary
EndoGastric Solutions has found a new approach to GERD surgery: trans-orally with an endoluminal approach. The new procedure should go minimally-invasive surgery one better, but in the process opens up a huge debate: will endoluminal GERD surgery be the province of gastric surgeons or gastroenterologists?
You may also be interested in...
EndoGastric Solutions Rewrites Playbook In Bid To Build GERD Business
Founded in 2001, EndoGastric Solutions Inc., a mature medical device company with $140 million in venture backing, hasn’t been able to secure a reliable source of reimbursement dollars for its EsophyX endoscopic treatment for GERD. Under new management, EGS is recommitting itself to collecting necessary clinical data and operating as a lean start-up as it makes its case for coverage and reimbursement with insurers.
Device Financings: Recent Growth, Future Opportunities
In Vivo analyzed recent public and private device financings to determine the comparative strengths and weaknesses of the various types of device financings, and further broke down the investments by therapeutic categories to examine what areas are hot and which ones are not. We found that the device industry has rebounded from a dismal public market and is showing strength among both public and private investors, resulting in a sector well-positioned for continued growth.
Crospon Ltd.
New imaging technology employed through a therapeutic endoscope provides the most relevant information to diagnose gastroesophageal reflux disease (GERD), according to its manufacturer, Crospon. Furthermore, the Irish start-up says its novel EndoFLIP (endoscopic functional lumen imaging probe) technology can be used to assist in GERD surgeries and to assess the results.